- cafead   Jul 17, 2023 at 07:12: PM
via An FDA accelerated approval in 2021 made Johnson & Johnson’s Rybrevant the first treatment for a specific subset of non-small cell lung cancer (NSCLC). Now, with a positive clinical trial readout, the company hopes to win a full approval and extend the drug to newly diagnosed patients.
article source
article source